Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedFeb 18, 2026
DataAggregated Company Financials
Companies318
  • 7D1.3%
  • 3M11.3%
  • 1Y30.9%
  • YTD5.7%

Johnson & Johnson is up 2.1%, leading the way for the Pharma industry, which has gained 1.3%. In the last 12 months, the industry was up 31%. As for the next few years, earnings are expected to grow by 11% per annum.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 19 Feb 2026US$2.4tUS$411.5bUS$73.9b20.1x32.3x5.8x
Sat, 17 Jan 2026US$2.3tUS$402.6bUS$71.5b20.7x31.8x5.7x
Mon, 15 Dec 2025US$2.2tUS$402.7bUS$71.4b19.7x30.8x5.5x
Wed, 12 Nov 2025US$2.0tUS$402.7bUS$71.3b18.1x28.2x5x
Fri, 10 Oct 2025US$1.9tUS$387.6bUS$61.0b18.8x31.3x4.9x
Sun, 07 Sep 2025US$1.8tUS$387.9bUS$61.0b19x29.2x4.6x
Tue, 05 Aug 2025US$1.7tUS$382.0bUS$54.8b18.2x31.5x4.5x
Thu, 03 Jul 2025US$1.7tUS$382.7bUS$61.3b18.3x28.4x4.5x
Sat, 31 May 2025US$1.7tUS$382.7bUS$61.2b17.8x27.2x4.4x
Mon, 28 Apr 2025US$1.8tUS$379.6bUS$63.1b16.2x28.5x4.7x
Wed, 26 Mar 2025US$1.9tUS$381.1bUS$41.3b17x46.1x5x
Fri, 21 Feb 2025US$1.9tUS$381.0bUS$39.0b18.3x47.8x4.9x
Sun, 19 Jan 2025US$1.8tUS$369.3bUS$31.2b18.9x56.1x4.7x
Tue, 17 Dec 2024US$1.8tUS$373.8bUS$30.7b18.9x59.3x4.9x
Thu, 14 Nov 2024US$1.9tUS$373.8bUS$30.7b20.5x61x5x
Sat, 12 Oct 2024US$2.0tUS$364.2bUS$25.3b18.7x79.2x5.5x
Mon, 09 Sep 2024US$2.0tUS$364.1bUS$25.5b17.8x79x5.5x
Wed, 07 Aug 2024US$1.9tUS$358.7bUS$21.7b15.5x85.8x5.2x
Fri, 05 Jul 2024US$1.9tUS$357.6bUS$13.8b15x140.4x5.4x
Sun, 02 Jun 2024US$1.9tUS$358.3bUS$14.1b15.9x133.4x5.2x
Tue, 30 Apr 2024US$1.8tUS$359.6bUS$17.5b23x102.8x5x
Thu, 28 Mar 2024US$1.9tUS$355.3bUS$22.6b19.4x84.3x5.4x
Sat, 24 Feb 2024US$1.9tUS$355.2bUS$24.0b24.1x80x5.4x
Mon, 22 Jan 2024US$1.8tUS$375.2bUS$33.9b27.7x51.8x4.7x
Wed, 20 Dec 2023US$1.7tUS$375.1bUS$33.9b26.9x49.4x4.5x
Fri, 17 Nov 2023US$1.6tUS$375.4bUS$33.7b25.8x48.5x4.3x
Sun, 15 Oct 2023US$1.7tUS$381.8bUS$43.8b18.3x38.9x4.5x
Tue, 12 Sep 2023US$1.8tUS$381.8bUS$43.9b18x40x4.6x
Thu, 10 Aug 2023US$1.8tUS$381.3bUS$44.5b19x40x4.7x
Sat, 08 Jul 2023US$1.7tUS$392.8bUS$60.2b19x27.7x4.2x
Mon, 05 Jun 2023US$1.7tUS$393.0bUS$60.5b18.9x28.3x4.4x
Wed, 03 May 2023US$1.7tUS$392.8bUS$59.8b17.5x28.4x4.3x
Fri, 31 Mar 2023US$1.6tUS$401.1bUS$69.5b15.7x22.5x3.9x
Sun, 26 Feb 2023US$1.6tUS$401.8bUS$68.5b17.4x23.1x3.9x
Price to Earnings Ratio

23.1x


Total Market Cap: US$1.6tTotal Earnings: US$68.5bTotal Revenue: US$401.8bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53.3x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 32.3x which is lower than its 3-year average PE of 53.2x.
  • The 3-year average PS ratio of 4.8x is lower than the industry's current PS ratio of 5.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 2.6% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.58%
Healthcare0.56%
Pharma1.27%
Pharma1.27%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
JNJ Johnson & JohnsonUS$243.332.1%
+US$12.1b		57.0%PE21.9x
MRK MerckUS$121.573.8%
+US$11.0b		46.0%PE16.5x
LLY Eli LillyUS$1.04k1.1%
+US$7.8b		20.9%PE44.8x
RGC Regencell Bioscience HoldingsUS$31.5718.2%
+US$2.4b		29,846.0%PB3212x
NKTR Nektar TherapeuticsUS$73.8231.8%
+US$926.3m		364.3%PS33x

Latest News

LLY
US$1,036.05
Eli Lilly
7D
1.1%
1Y
20.9%
JNJ
US$243.33
Johnson & Johnson
7D
2.1%
1Y
57.0%
MRK
US$121.57
Merck
7D
3.8%
1Y
46.0%
BMY
US$60.35
Bristol-Myers Squibb
7D
-0.8%
1Y
10.9%

We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit

Feb 18
We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit
NKTR
US$73.82
Nektar Therapeutics
7D
31.8%
1Y
364.3%
PFE
US$27.37
Pfizer
7D
-0.9%
1Y
7.1%
OCUL
US$6.99
Ocular Therapeutix
7D
-22.6%
1Y
-2.9%

OCUL: Potential Higher Sanofi Bid Will Drive Bullish Repricing

Analysts have adjusted their price target on Ocular Therapeutix to $20.00 from $19.00, reflecting updated assumptions around revenue growth, profit margins, discount rate and future P/E that they view as more closely aligned with the company’s current outlook. What's in the News Sanofi is reported to be preparing a higher bid for Ocular Therapeutix, signaling continuing interest in the company as a potential acquisition target (IBD, Periodicals).
ZTS
US$125.56
Zoetis
7D
-2.0%
1Y
-19.8%
RPRX
US$45.41
Royalty Pharma
7D
2.7%
1Y
38.2%
VTRS
US$15.74
Viatris
7D
-2.4%
1Y
44.0%
MANE
US$47.38
Veradermics
7D
17.1%
1Y
n/a
CRNX
US$43.68
Crinetics Pharmaceuticals
7D
-8.3%
1Y
19.3%
LQDA
US$33.84
Liquidia
7D
-16.5%
1Y
105.7%
SEPN
US$30.30
Septerna
7D
13.5%
1Y
341.0%
RGC
US$31.57
Regencell Bioscience Holdings
7D
18.2%
1Y
29,846.0%
GPCR
US$71.41
Structure Therapeutics
7D
-9.1%
1Y
214.3%